Charles Schwab
PGNX

Charles Schwab’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Charles Schwab’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-543,870
Closed -$2.07M – 3402
2020
Q1 		$2.07M Buy
543,870
+8,689
+2% +$37.4K ﹤0.01% 2265
2019
Q4 		$2.73M Buy
535,181
+18,009
+3% +$95.3K ﹤0.01% 2319
2019
Q3 		$2.62M Buy
517,172
+32,744
+7% +$163K ﹤0.01% 2295
2019
Q2 		$2.99M Buy
484,428
+960
+0.2% +$4.63K ﹤0.01% 2211
2019
Q1 		$2.24M Buy
483,468
+33,478
+7% +$151K ﹤0.01% 2331
2018
Q4 		$1.89M Sell
449,990
-5,748
-1% -$29.3K ﹤0.01% 2352
2018
Q3 		$2.86M Buy
455,738
+64,393
+16% +$495K ﹤0.01% 2308
2018
Q2 		$3.15M Buy
391,345
+29,724
+8% +$227K ﹤0.01% 2219
2018
Q1 		$2.7M Buy
361,621
+36,265
+11% +$241K ﹤0.01% 2217
2017
Q4 		$1.94M Buy
325,356
+2,932
+0.9% +$17.8K ﹤0.01% 2313
2017
Q3 		$2.37M Buy
322,424
+15,581
+5% +$99K ﹤0.01% 2227
2017
Q2 		$2.08M Sell
306,843
-35,361
-10% -$261K ﹤0.01% 2209
2017
Q1 		$3.23M Buy
342,204
+67,271
+24% +$671K ﹤0.01% 1991
2016
Q4 		$2.38M Sell
274,933
-21,294
-7% -$157K ﹤0.01% 2110
2016
Q3 		$1.88M Buy
296,227
+79,127
+36% +$478K ﹤0.01% 2160
2016
Q2 		$917K Buy
217,100
+114,500
+112% +$553K ﹤0.01% 2378
2016
Q1 		$448K Hold
102,600
– – ﹤0.01% 2620
2015
Q4 		$629K Sell
102,600
-3,400
-3% -$22.3K ﹤0.01% 2543
2015
Q3 		$607K Sell
106,000
-173,664
-62% -$1.33M ﹤0.01% 2548
2015
Q2 		$2.09M Hold
279,664
– – ﹤0.01% 2073
2015
Q1 		$1.67M Buy
279,664
+173,664
+164% +$1.09M ﹤0.01% 2150
2014
Q4 		$802K Hold
106,000
– – ﹤0.01% 2444
2014
Q3 		$551K Hold
106,000
– – ﹤0.01% 2552
2014
Q2 		$457K Hold
106,000
– – ﹤0.01% 2666
2014
Q1 		$434K Buy
106,000
+21,100
+25% +$108K ﹤0.01% 2647
2013
Q4 		$453K Hold
84,900
– – ﹤0.01% 2627
2013
Q3 		$405K Buy
84,900
+19,600
+30% +$106K ﹤0.01% 2629
2013
Q2 		$303K Buy
+65,300
New +$293K ﹤0.01% 2726

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Charles Schwab's PGNX Position: Q2 2020 in Review

Charles Schwab sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 543,870 shares — an estimated $2.07M sold.

Charles Schwab first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $3.23M in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Charles Schwab reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Charles Schwab sold 543,870 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $2.07M.
  • Charles Schwab first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
  • Charles Schwab's Progenics Pharmaceuticals Inc position peaked at $3.23M in Q1 2017.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Charles Schwab's 13F filing for Q2 2020, filed 14 Aug 2020.